Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julien Seneschal

Showing results (81-90 of 182) with videos related to

Pageof 19
Sort By:
JCI Insight|January 25, 2019
Disrupting the IL-36 and IL-23/IL-17 loop underlies the efficacy of calcipotriol and corticosteroid therapy for psoriasisBeatriz Germán, Ruicheng Wei, Pierre Hener, et al.
The British Journal of Dermatology|August 18, 2024
The atopic dermatitis patient journey: insights from a qualitative studyFanny C Kpenou, Carle Paul, Julien Seneschal, et al.
The Journal of Investigative Dermatology|February 7, 2021
Efficacy and Safety of Tacrolimus 0.1% for the Treatment of Facial Vitiligo: A Multicenter Randomized, Double-Blinded, Vehicle-Controlled StudyJulien Seneschal, Alexandra Duplaine, Hervé Maillard, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 16, 2024
Repigmentation by body region in patients with vitiligo treated with ruxolitinib cream over 52 weeksThierry Passeron, John E Harris, Amit G Pandya, et al.
Allergy|June 18, 2021
Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccineAnne-Sophie Darrigade, Hélène Théophile, Paola Sanchez-Pena, et al.
Annals of the Rheumatic Diseases|January 6, 2019
Rituximab in moderate to severe non-renal systemic lupus erythematosus: a reanalysis of the EXPLORER studyMarc Scherlinger, Claire Carcaud, Marie-Elise Truchetet, et al.
Journal of the American Academy of Dermatology|February 15, 2019
Cross-cultural validation of a short-form of the Vitiligo Impact Patient scale (VIPs)Khaled Ezzedine, Maggi Ahmed, Andrea Tovar-Garza, et al.
Dermatology and Therapy|March 29, 2025
Efficacy and Safety of Ruxolitinib Cream in Vitiligo by Patient Characteristic Subgroups: Descriptive Pooled Analysis From Two Phase 3 StudiesJulien Seneschal, Albert Wolkerstorfer, Seemal R Desai, et al.
The Journal of Dermatological Treatment|October 30, 2025
A CollaboraTive Initiative of worldwide Vitiligo Experts and patients to define vitiligo activity (ACTIVE): study protocolLiesbeth Delbaere, Lise Vanden Broucke, Albert Wolkerstorfer, et al.
Journal of the American Academy of Dermatology|January 18, 2017
Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligoMaiana Larsabal, Aurélie Marti, Clément Jacquemin, et al.
Pageof 19

Showing results (81-90 of 182) with videos related to

Sort By:
Pageof 19
JCI Insight|January 25, 2019
Disrupting the IL-36 and IL-23/IL-17 loop underlies the efficacy of calcipotriol and corticosteroid therapy for psoriasisBeatriz Germán, Ruicheng Wei, Pierre Hener, et al.
The British Journal of Dermatology|August 18, 2024
The atopic dermatitis patient journey: insights from a qualitative studyFanny C Kpenou, Carle Paul, Julien Seneschal, et al.
The Journal of Investigative Dermatology|February 7, 2021
Efficacy and Safety of Tacrolimus 0.1% for the Treatment of Facial Vitiligo: A Multicenter Randomized, Double-Blinded, Vehicle-Controlled StudyJulien Seneschal, Alexandra Duplaine, Hervé Maillard, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 16, 2024
Repigmentation by body region in patients with vitiligo treated with ruxolitinib cream over 52 weeksThierry Passeron, John E Harris, Amit G Pandya, et al.
Allergy|June 18, 2021
Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccineAnne-Sophie Darrigade, Hélène Théophile, Paola Sanchez-Pena, et al.
Annals of the Rheumatic Diseases|January 6, 2019
Rituximab in moderate to severe non-renal systemic lupus erythematosus: a reanalysis of the EXPLORER studyMarc Scherlinger, Claire Carcaud, Marie-Elise Truchetet, et al.
Journal of the American Academy of Dermatology|February 15, 2019
Cross-cultural validation of a short-form of the Vitiligo Impact Patient scale (VIPs)Khaled Ezzedine, Maggi Ahmed, Andrea Tovar-Garza, et al.
Dermatology and Therapy|March 29, 2025
Efficacy and Safety of Ruxolitinib Cream in Vitiligo by Patient Characteristic Subgroups: Descriptive Pooled Analysis From Two Phase 3 StudiesJulien Seneschal, Albert Wolkerstorfer, Seemal R Desai, et al.
The Journal of Dermatological Treatment|October 30, 2025
A CollaboraTive Initiative of worldwide Vitiligo Experts and patients to define vitiligo activity (ACTIVE): study protocolLiesbeth Delbaere, Lise Vanden Broucke, Albert Wolkerstorfer, et al.
Journal of the American Academy of Dermatology|January 18, 2017
Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligoMaiana Larsabal, Aurélie Marti, Clément Jacquemin, et al.
Pageof 19